Leistungsparameter und Erregernachweise in unterschiedlich geimpften Tiergruppen in Bezug auf das Porzine Circovirus Typ 2 und Mycoplasma hyopneumoniae

Zusammenfassung

Gegenstand und Ziel Atemwegserkrankungen, meist multifaktoriell bedingt, führen weltweit zu Problemen in Schweinepopulationen. Infektiöse Ursachen, wie das Porzine Circovirus Typ 2 (PCV2) und Mycoplasma hyopneumoniae (M. hyopneumoniae) können neben Management-, Haltungs- und Umweltfaktoren an der Krankheitsentstehung beteiligt sein. In einem konventionell wirtschaftenden, kombinierten Betrieb in Niedersachsen, auf dem die Ferkel nicht gegen PCV2 geimpft wurden, sollte überprüft werden, inwiefern die Einführung einer Impfung gegen PCV2 (Suvaxyn^® Circo + MH RTU, Zoetis) einen Effekt auf die Tiergesundheit hat und wie die Wirkung dieses Kombinationsimpfstoffes im Vergleich zu simultan verabreichten Monoimpfstoffen gegen PCV2 und M. hyopneumoniae zu bewerten ist.

Material und Methoden In einem zweiphasigen Versuch wurden 524 (Phase 1) bzw. 521 (Phase 2) klinisch gesunde Ferkel in der ersten Lebenswoche eingeschlossen. In der ersten Phase wurden Leistungsparameter bei Tieren verglichen, die nur gegen M. hyopneumoniae (Gruppe A) bzw. gegen PCV2 und M. hyopneumoniae (Gruppe B) geimpft worden waren. In Phase 2 wurden Impfungen gegen PCV2 und M. hyopneumoniae mit unterschiedlichen Impfstoffen verglichen (Gruppen C und D). Die Leistungsparameter umfassten die Verluste über die gesamte Lebensdauer der Tiere, die täglichen Zunahmen in der Säugephase, Aufzucht und Mast, sowie die stichprobenartig erfasste Erregerlast im Serum (PCV2) oder im Tracheobronchialsekret (M. hyopneumoniae). Zusätzlich wurde eine Beurteilung der Schlachtlungen durchgeführt.

Ergebnisse In der ersten Phase zeigte sich, dass die Gruppe, die die PCV2-Impfung erhalten hatte (Gruppe B: Suvaxyn^® Circo + MH RTU) in den Endmast- (+ 37 g, p = 0,012) und in den täglichen Gesamtzunahmen (+ 16 g, p = 0,013) einen signifikanten Unterschied zur Gruppe ohne PCV2-Impfung (Gruppe A) aufwies. In Gruppe A konnte signifikant häufiger eine PCV2-Virämie nachgewiesen werden. In der zweiten Phase konnte gezeigt werden, dass Gruppe D dem etablierten Impfschema von Gruppe C nicht unterlegen war. Nachweisraten für M. hyopneumoniae in den Tracheobronchialsekreten lagen bei Endmastschweinen in der 22. Lebenswoche gruppenübergreifend zwischen 27–80 %.

Schlussfolgerung Die Einführung einer Impfung gegen PCV2 führte zu einer verbesserten Tiergesundheit und zu höheren täglichen Zunahmen.

Klinische Relevanz Mit dem hier untersuchten Kombinationsimpfstoff steht Landwirten und Tierärzten eine weitere Möglichkeit zur Verbesserung der Tiergesundheit in der Schweinehaltung zur Verfügung.

Abstract

Objective Respiratory diseases, mostly multifactorial, cause problems in pig farms worldwide. Next to infectious agents, such as Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyopneumoniae) management, housing, and environmental factors are decisive for the development of disease. In a conventional, closed swine farm in Lower Saxony, Germany, which did not vaccinate against PCV2, the effect of an implementation of PCV2 vaccination (Suvaxyn^® Circo + MH RTU) onto animal health was evaluated. In addition, the effect of this combination vaccine was assessed in comparison to simultaneous administration of mono-vaccines against PCV2 and M. hyopneumoniae.

Material and method In a two-phase trial, 524 (phase 1) or 521 (phase 2) clinically healthy piglets were included at the first week of life. In the first phase, performance parameters were compared in animals vaccinated against M. hyopneumoniae only (group A) or vaccinated against PCV2 and M. hyopneumoniae (group B). In phase 2, vaccination against PCV2 and M. hyopneumoniae with different vaccines were compared (groups C and D). Performance parameters included lifetime animal losses, daily weight gains during suckling, weaning and fattening, and randomly sampled pathogen loads in serum (PCV2) or tracheobronchial secretions (M. hyopneumoniae). In addition, an assessment of the lungs was performed after slaughter.

Results In the first phase, it was shown that the group vaccinated against PCV2 (Group B: Suvaxyn^® Circo + MH RTU) had higher daily growth rates during the fattening period (+ 37 g, p = 0.012) as well as during the complete period (+ 16 g, p = 0.013) in comparison to the group without PCV2 vaccination (Group A). In group A a significantly higher proportion of animals showed a PCV2 viremia. In the second phase, it was shown that group D was not inferior to the established vaccination regiment of group C. In fattening pigs in week 22 of life, detection rates for M. hyopneumoniae in tracheobronchial secretions were in the range of 27–80 % irrespective of the vaccination group.

Conclusion Vaccination against PCV2 leads to improved animal health and higher daily weight gains.

Clinical relevance The combined vaccine studied here provides farmers and veterinarians with an additional option for the improvement of animal health in pig production.

Schlüsselwörter

Serologie - Virämie - tägliche Zunahmen - Tracheobronchialsekret - Lungenbefunde

Key words

Serology - viremia - daily weight gain - tracheobronchial secretions - lung alterations

Publication History

Received: 18 May 2021

Accepted: 28 July 2021

Article published online:
02 March 2022

• Literatur

• 1 Gillespie J, Opriessnig T, Meng XJ. et al. Porcine circovirus type 2 and porcine circovirus-associated disease. J Vet Intern Med 2009; 23: 1151-1163 DOI: 10.1111/j.1939-1676.2009.0389.x.
• 2 Segales J. Porcine circovirus type 2 (PCV2) infections: clinical signs, pathology and laboratory diagnosis. Virus Res 2012; 164: 10-19 DOI: 10.1016/j.virusres.2011.10.007.
• 3 Opriessnig T, Giménez-Lirola LG, Halbur PG. Polymicrobial respiratory disease in pigs. Anim Health Res Rev 2011; 12: 133-148 DOI: 10.1017/s1466252311000120.
• 4 Eddicks M, Eddicks L, Stadler J. et al. Der Porcine Respiratory Disease Complex (PRDC) – eine klinische Übersicht. Tierarztl Prax Ausg G Grosstiere Nutztiere 2021; 49: 120-132
• 5 Sibila M, Pieters M, Molitor T. et al. Current perspectives on the diagnosis and epidemiology of Mycoplasma hyopneumoniae infection. Vet J 2009; 181: 221-231 DOI: 10.1016/j.tvjl.2008.02.020.
• 6 Maes D, Segales J, Meyns T. et al. Control of Mycoplasma hyopneumoniae infections in pigs. Vet Microbiol 2008; 126: 297-309 DOI: 10.1016/j.vetmic.2007.09.008.
• 7 Simionatto S, Marchioro SB, Maes D. et al. Mycoplasma hyopneumoniae: from disease to vaccine development. Vet Microbiol 2013; 165: 234-242 DOI: 10.1016/j.vetmic.2013.04.019.
• 8 Pausenberger A, Mues G, Nienhoff H. et al. Comparison of PCR-results of broncho-alveolar-lavage samples and tracheo-bronchial-swab samples in a pig farm. Prakt Tierarzt 2012; 93: 440-447
• 9 Steinmann T, Blaha T, Meemken D. A simplified evaluation system of surface-related lung lesions of pigs for official meat inspection under industrial slaughter conditions in Germany. BMC Vet Res 2014; 10: 98 DOI: 10.1186/1746-6148-10-98.
• 10 Fort M, Sibila M, Allepuz A. et al. Porcine circovirus type 2 (PCV2) vaccination of conventional pigs prevents viremia against PCV2 isolates of different genotypes and geographic origins. Vaccine 2008; 26: 1063-1071 DOI: 10.1016/j.vaccine.2007.12.019.
• 11 Afghah Z, Webb B, Meng XJ. et al. Ten years of PCV2 vaccines and vaccination: Is eradication a possibility?. Vet Microbiol 2017; 206: 21-28 DOI: 10.1016/j.vetmic.2016.10.002.
• 12 Karuppannan AK, Opriessnig T. Porcine Circovirus Type 2 (PCV2) Vaccines in the Context of Current Molecular Epidemiology. Viruses 2017; 9 DOI: 10.3390/v9050099.
• 13 Maes D, Sibila M, Kuhnert P. et al. Update on Mycoplasma hyopneumoniae infections in pigs: Knowledge gaps for improved disease control. Transbound Emerg Dis 2018; 65 (Suppl. 01) 110-124 DOI: 10.1111/tbed.12677.
• 14 Leal Zimmer FMA, Paes JA, Zaha A. et al. Pathogenicity & virulence of Mycoplasma hyopneumoniae. Virulence 2020; 11: 1600-1622 DOI: 10.1080/21505594.2020.1842659.
• 15 Göller M, Fels M, Gerdts WR. et al. Intradermal versus intramuscular vaccine application in suckling piglets – Comparison with regard to dermal reactions, performance and procedural aspects. Tierarztl Prax Ausg G Grosstiere Nutztiere 2018; 46: 317-322 DOI: 10.15653/tpg-180461.
• 16 Temple D, Escribano D, Jiménez M. et al. Effect of the needle-free “intra dermal application of liquids” vaccination on the welfare of pregnant sows. Porcine Health Manag 2017; 3: 9 DOI: 10.1186/s40813-017-0056-3.
• 17 Beneteau E, Peduzzi M, Peroz D. et al. Effect of two different vaccine combinations against PCV2 and Mycoplasma hyopneumoniae (MHYO) on pigs’ well-being. In, 10th European Symposium of Porcine Health Management; Barcelona: 2018
• 18 Froehlich S, Zoels S, Eddicks M. et al. Comparison of the efficacy of two ready-to-use vaccines against Mycoplasma hyopneumoniae and PCV2 under field conditions in Germany. In, 10th European Symposium of Porcine Health Management; Barcelona: 2018
• 19 Froehlich S, Zoels S, Banholzer E. et al. Comparative field study on evaluating the efficacy of two different two shot M. hyopneumoniae vaccination schemes, one incorporating a PCV2/M. hyo ready to use combinant product. In, 10th European Symposium of Porcine Health Management; Barcelona: 2018
• 20 Spindler C, Morin J, Guéguen JM. et al. Results of vaccination with Suvaxyn^® Circo + MH RTU in a pilot group of farms: longitudinal study of growth performance per batch. In, 10th European Symposium of Porcine Health Management; Barcelona: 2018
• 21 Spindler C, Ledoux AL, Colin F. Results of vaccination with Suvaxyn^® Circo + MH RTU in a pilot-group of farms: longitudinal study of lung lesions at the slaughterhouse. In, 10th European Symposium of Porcine Health Management; Barcelona: 2018
• 22 Park C, Jeong J, Choi K. et al. Efficacy of a new bivalent vaccine of porcine circovirus type 2 and Mycoplasma hyopneumoniae (Fostera™ PCV MH) under experimental conditions. Vaccine 2016; 34: 270-275 DOI: 10.1016/j.vaccine.2015.11.034.
• 23 Nathues H. Labordiagnostik in Schweinebeständen. Prakt Tierarzt 2015; 609-622
• 24 Blaha T, Neubrand J. Die duchgängige Qualitätssicherung bei der Schweinefleischproduktion. Prakt Tierarzt 1994; 75: 57-61
• 25 Brunborg IM, Moldal T, Jonassen CM. Quantitation of porcine circovirus type 2 isolated from serum/plasma and tissue samples of healthy pigs and pigs with postweaning multisystemic wasting syndrome using a TaqMan-based real-time PCR. J Virol Methods 2004; 122: 171-178 DOI: 10.1016/j.jviromet.2004.08.014.
• 26 Harding JC, Baker CD, Tumber A. et al. Porcine circovirus-2 DNA concentration distinguishes wasting from nonwasting pigs and is correlated with lesion distribution, severity, and nucleocapsid staining intensity. J Vet Diagn Invest 2008; 20: 274-282 DOI: 10.1177/104063870802000303.
• 27 Olvera A, Sibila M, Calsamiglia M. et al. Comparison of porcine circovirus type 2 load in serum quantified by a real time PCR in postweaning multisystemic wasting syndrome and porcine dermatitis and nephropathy syndrome naturally affected pigs. J Virol Methods 2004; 117: 75-80 DOI: 10.1016/j.jviromet.2003.12.007.
• 28 Dubosson CR, Conzelmann C, Miserez R. et al. Development of two real-time PCR assays for the detection of Mycoplasma hyopneumoniae in clinical samples. Vet Microbiol 2004; 102: 55-65 DOI: 10.1016/j.vetmic.2004.05.007.
• 29 Kixmoller M, Ritzmann M, Eddicks M. et al. Reduction of PMWS-associated clinical signs and co-infections by vaccination against PCV2. Vaccine 2008; 26: 3443-3451 DOI: 10.1016/j.vaccine.2008.04.032.
• 30 Fachinger V, Bischoff R, Jedidia SB. et al. The effect of vaccination against porcine circovirus type 2 in pigs suffering from porcine respiratory disease complex. Vaccine 2008; 26: 1488-1499 DOI: 10.1016/j.vaccine.2007.11.053.
• 31 Fort M, Sibila M, Perez-Martin E. et al. One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model. Vaccine 2009; 27: 4031-4037 DOI: 10.1016/j.vaccine.2009.04.028.
• 32 Beach NM, Meng XJ. Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2 (PCV2). Virus Res 2012; 164: 33-42 DOI: 10.1016/j.virusres.2011.09.041.
• 33 Eddicks M, Szikora F, Walhofer N. et al. Occurrence of genotypes of porcine circovirus (PCV2) in pig farms using different vaccination strategies against PCV2. Tierarztl Prax Ausg G Grosstiere Nutztiere 2017; 45: 90-97 DOI: 10.15653/tpg-160547.
• 34 Fablet C, Marois C, Kobisch M. et al. Estimation of the sensitivity of four sampling methods for Mycoplasma hyopneumoniae detection in live pigs using a Bayesian approach. Vet Microbiol 2010; 143: 238-245 DOI: 10.1016/j.vetmic.2009.12.001.
• 35 Mues G, Mesu AP, Tegeler R. et al. Aussagekraft von Lungenbefundungen am Schlachthof im Vergleich zur Befundung in der Pathologie unter Berücksichtigung weiterführender diagnostischer Methoden beim Schwein. Prakt Tierarzt 2014; 634 ff.
• 36 Tassis PD, Tsakmakidis I, Papatsiros VG. et al. A randomized controlled study on the efficacy of a novel combination vaccine against enzootic pneumonia (Mycoplasma hyopneumoniae) and porcine Circovirus type 2 (PCV2) in the presence of strong maternally derived PCV2 immunity in pigs. BMC Vet Res 2017; 13: 91 DOI: 10.1186/s12917-017-1014-7.
• 37 Feng H, Blanco G, Segales J. et al. Can Porcine circovirus type 2 (PCV2) infection be eradicated by mass vaccination?. Vet Microbiol 2014; 172: 92-99 DOI: 10.1016/j.vetmic.2014.05.003.
• 38 Madec F, Eveno E, Morvan P. et al. La Maladie de l’Amaigrissement du Porcelet (MAP) en France. 1. Aspects descriptifs, impact en elevage. In: France: Institut Technique du porc; 1999: 347